Professor of Respiratory Medicine
Professor Pavord has a particular interest in asthma, chronic pulmonary disease and chronic cough. He is an internationally renowned researcher in these areas and has played a lead role in developing three of the most promising emerging treatments. He has published 350 scientific papers, including three of the 20 most cited papers in the field in the last 10 years. He has an H-index of 74. His main contribution has been to develop new methods to assess and treat airway inflammation and airway diseases.
He has been joint Chief Medical Advisor to Asthma UK since May 2008 and joint Editor of Thorax since 2010.
in 2016 Professor Pavord was awarded The ERS Gold Medal in Asthma in recognition of his outstanding contribution in the field of asthma research.
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA. et al, (2020), The Lancet. Respiratory medicine
Biomarkers of Type 2 Airway Inflammation in Airway Disease: And Then There Were Two.
Pavord ID. and Corren J., (2020), The journal of allergy and clinical immunology. In practice, 8, 2640 - 2642
Blood Eosinophil-directed Management of Airway Disease. The Past, Present, and Future.
Pavord ID., (2020), American journal of respiratory and critical care medicine, 202, 637 - 639
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.
Pavord ID. et al, (2020), The Lancet. Respiratory medicine, 8, 671 - 680
The burden of exacerbations in mild asthma: a systematic review.
FitzGerald JM. et al, (2020), ERJ open research, 6